Structure Therapeutics, Inc. Sponsored ADR (GPCR) AI Stock Analysis

• Market Cap: $2.18B
• Dividend Yield: N/A
• Average Volume (3M): 906.74K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.30
• Revenue Growth: N/A
• EPS Growth: -64.91%
• Country: US
• Employees: 163
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -1.13
• Shares Outstanding: 60,677,640
• 10 Day Avg. Volume: 891,974
• 30 Day Avg. Volume: 906,737
• PEG Ratio: 3.15
• Price to Book (P/B): 1.65
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -12.11
• Enterprise Value/Market Cap: 0.39
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -1.23K
• Enterprise Value/Ebitda: -3.55
• 1Y Price Target: $69.57
• Price Target Upside: 98.77% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 9
• EPS Forecast (FY): -1.39
• Revenue Forecast (FY): N/A

• Rating: 31 Underperform
• Price Target: ―

Structure Therapeutics, Inc.'s overall score is largely impacted by its financial performance, reflecting significant financial sustainability risks due to zero revenues and increasing losses, despite strong cash positions. The technical analysis provides a mixed view with some short-term momentum but longer-term concerns. The valuation remains challenging with a negative P/E ratio, indicating a speculative investment reliant on future success in R&D and commercialization.

Positive Factors

Strong Cash Position

A robust cash position provides the company with the necessary resources to fund R&D and operations, crucial for sustaining growth and innovation in the biotech sector.

Low Leverage

Low leverage reduces financial risk and provides flexibility in financing future growth initiatives, enhancing long-term stability and operational resilience.

Innovative Business Model

Targeting GPCRs positions the company at the forefront of addressing significant health challenges, potentially leading to breakthrough therapies and competitive advantages.

Negative Factors

Zero Revenue

The absence of revenue highlights the company's reliance on future product approvals and partnerships, posing a risk to financial sustainability if commercialization is delayed.

Increasing Losses

Rising losses reflect high R&D and operational costs without immediate income, stressing the need for successful product development and market entry to achieve profitability.

Negative Cash Flow

Negative cash flow indicates a dependency on external financing, which could be challenging if future funding rounds are not successful, impacting long-term viability.

Structure Therapeutics, Inc. Sponsored ADR Business Overview & Revenue Model

Company Description

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. The company is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist, targeting apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension; and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was founded in 2016 and is headquartered in South San Francisco, California.

How the Company Makes Money

Structure Therapeutics, Inc. generates revenue through the development and commercialization of its drug candidates. The company makes money by advancing its compounds through clinical trials and seeking regulatory approval for market entry. Once approved, these drugs can be licensed or sold to pharmaceutical companies or healthcare providers, generating income through sales, royalties, or milestone payments. Additionally, the company may engage in strategic partnerships or collaborations with other biopharmaceutical firms, which can provide funding, shared resources, and expertise in exchange for a share in the profits or rights to market the developed therapies. These partnerships and collaborations often play a significant role in the company's revenue model, offering both financial support and expanded market reach.

Structure Therapeutics, Inc. Sponsored ADR Financial Statement Overview

Summary

Structure Therapeutics, Inc. is in a typical biotechnology growth phase with heavy reliance on external financing to support operations and R&D, evident from zero revenues and increasing losses. While the balance sheet shows strong liquidity due to financing, the absence of operating income and negative cash flows underscore financial sustainability risks. Investors must consider the company's future ability to generate revenue and control costs as it progresses through its development pipeline.

Income Statement

The company has consistently reported zero revenue over the analyzed periods, indicating a lack of commercial product or service sales, typical for early-stage biotech firms. Net losses have widened significantly from $15,876 in 2020 to $122,526,000 in 2024, showing increased expenses likely related to R&D and operational scaling. This trajectory signals an aggressive investment phase with high cash burn without immediate income generation.

Balance Sheet

The balance sheet shows strong cash positions with cash and equivalents increasing from $37,445 in 2020 to $883,518,000 in 2024, largely due to financing activities, which is crucial for the company's operations given the lack of revenue. The debt-to-equity ratio has improved as equity turned positive in recent years, but total debt remains low compared to equity, indicating low leverage. However, the negative historical equity values raise concerns about prior financial stability.

Cash Flow

Operating cash flow remains negative, reflecting the company's ongoing investment in R&D and operations without corresponding income. Free cash flow is consistently negative, indicating continued cash burn. The company relies heavily on financing activities to fund operations, as evidenced by significant cash inflows from financing. This dependency poses a risk if future financing rounds are not successful.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	-686.98K	0.00	0.00	0.00	0.00	-20.03K
EBITDA	-238.30M	-157.24M	-102.48M	-52.28M	-37.62M	-15.75M
Net Income	-210.69M	-122.53M	-89.62M	-51.32M	-40.01M	-15.90M
Balance Sheet
Total Assets	832.16M	903.33M	482.02M	97.84M	111.16M	38.70M
Cash, Cash Equivalents and Short-Term Investments	799.04M	883.52M	467.32M	90.84M	107.31M	37.45M
Total Debt	7.09M	3.86M	5.45M	260.00K	621.00K	280.00K
Total Liabilities	62.14M	38.49M	29.05M	212.99M	175.89M	61.17M
Stockholders Equity	770.02M	864.84M	452.97M	-115.14M	-64.73M	-22.47M
Cash Flow
Free Cash Flow	-196.38M	-117.93M	-81.66M	-46.27M	-33.37M	-14.30M
Operating Cash Flow	-194.25M	-116.64M	-79.49M	-46.12M	-32.16M	-14.28M
Investing Cash Flow	66.89M	-358.91M	-268.34M	-62.11M	17.86M	-21.15M
Financing Cash Flow	58.14M	515.26M	451.53M	29.01M	103.25M	25.84M

Structure Therapeutics, Inc. Sponsored ADR Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 35.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GPCR, the sentiment is Positive. The current price of 35 is above the 20-day moving average (MA) of 30.97, above the 50-day MA of 27.55, and above the 200-day MA of 22.88, indicating a bullish trend. The MACD of 2.22 indicates Negative momentum. The RSI at 66.72 is Neutral, neither overbought nor oversold. The STOCH value of 88.51 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GPCR.

Structure Therapeutics, Inc. Sponsored ADR Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CVAC	70 Outperform	$1.20B	5.84	―	―	799.36%	―
STOK	62 Neutral	$1.44B	39.51	15.02%	―	1128.17%	―
ZYME	54 Neutral	$1.46B	―	-18.46%	―	116.21%	43.93%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SNDX	48 Neutral	$1.46B	―	-129.32%	―	597.19%	0.45%
ETNB	42 Neutral	―	―	-86.86%	―	―	-82.75%
GPCR	31 Underperform	$2.18B	―	-25.31%	―	―	-64.91%

Structure Therapeutics, Inc. Sponsored ADR Corporate Events

Structure Therapeutics Advances Obesity Treatment Candidate

Structure Therapeutics Inc. has announced the selection of ACCG-2671, an oral small molecule amylin receptor agonist, as its lead candidate for obesity treatment. Preclinical studies show ACCG-2671’s effectiveness in weight loss with a favorable safety profile, supporting once-daily dosing. The company plans to initiate Phase 1 clinical trials by the end of 2025. This advancement positions Structure Therapeutics as a leader in developing amylin-based treatments that could significantly impact the treatment landscape for obesity and related conditions.